Pluri Inc. Watch

from 8-K 43 pages Pluri Inc. Common Shares Sales Agreement

from S-3 39 pages Pluristem Therapeutics Inc., a Nevada Corporation (The “Company”), Proposes, Subject to the Terms and Conditions Stated Herein, to Issue and Sell From Time to Time Through Jefferies LLC, as Sales Agent and/or Principal (The “Agent”), Shares of the Company’s Common Stock, Par Value $0.00001 Per Share (The “Common Shares”), on the Terms Set Forth in This Agreement (This “Agreement”). Section 1. Definitions (A) Certain Definitions. for Purposes of This Agreement, Capitalized Terms Used Herein and Not Otherwise Defined Shall Have the Following Respective Meanings

from 8-K 60 pages Pluristem Therapeutics Inc. 27,142,858 Shares and Warrants to Purchase 27,142,858 Shares Underwriting Agreement

from 10-Q 37 pages Open Market Sale Agreementsm

from 8-K 2 pages Agreement Signed and Executed on October 29, 2017

from 8-K 43 pages Pluristem Therapeutics Inc. Common Stock (Par Value $0.00001 Per Share) at Market Issuance Sales Agreement

from 8-K 38 pages Execution Version 12,244,898 Shares and Warrants to Purchase 7,346,939 Shares Pluristem Therapeutics Inc. Amended and Restated Underwriting Agreement

from 8-K 38 pages 8,163,265 Shares and Warrants to Purchase 4,897,959 Shares Pluristem Therapeutics Inc. Underwriting Agreement

from 8-K 13 pages This Letter (The “Agreement”) Constitutes the Agreement Between Maxim Group LLC (“Maxim” or the “Placement Agent”) and Pluristem Therapeutics Inc. (The “Company”), That Maxim Shall Serve as the Lead Placement Agent for the Company, on a “Reasonable Best Efforts” Basis, in Connection With the Proposed Placement (The “Placement”) of (I) Registered Shares (The “Shares”) of the Company’s Common Stock, Par Value $0.001 Per Share (The “Common Stock”), and (II) Warrants (The “Warrants”) to Purchase Shares of Common Stock (The Shares of Common Stock Underlying the Warrants, “Warrant Shares” And, Together With the Shares and the Warrants, the “Securities”). the Terms of the Placement and the Securities Shall Be Mutually Agreed Upon by the Company and the Purchasers (Each, a “Purchaser” and Collectively, the “Purchasers”) and Nothing Herein Constitutes That Maxim Would Have the Power or Authority to Bind the Company or Any Purchaser or an Obligation for the Company to Issue Any Securities or Complete the Placement. This Agreement and the Documents Executed and Delivered by the Company and the Purchasers in Connection With the Placement Shall Be Collectively Referred to Herein as the “Transaction Documents.” the Date of the Closing of the Placement Shall Be Referred to Herein as the “Closing Date.” the Company Expressly Acknowledges and Agrees That Maxim’s Obligations Hereunder Are on a Reasonable Best Efforts Basis Only and That the Execution of This Agreement Does Not Constitute a Commitment by Maxim to Purchase the Securities and Does Not Ensure the Successful Placement of the Securities or Any Portion Thereof or the Success of Maxim With Respect to Securing Any Other Financing on Behalf of the Company. the Placement Agent May Retain Other Brokers or Dealers to Act as Sub-Agents or Selected-Dealers on Its Behalf in Connection With the Placement

from 8-K 35 pages 8,000,000 Shares and Warrants to Purchase 2,800,000 Shares Pluristem Therapeutics Inc. Underwriting Agreement

from 8-K 32 pages Pluristem Therapeutics Inc. 11,000,000 Shares and Warrants to Purchase 4,400,000 Shares Underwriting Agreement

from 8-K ~20 pages Placement Agency Agreement October 6, 2009

from 8-K ~20 pages Confidential Yaky Yanay Chief Financial Officer Pluristem Therapeutics Inc. Matam Advanced Technology Park # 20 Haifa 31905, Israel Dear Mr. Yanay

from 8-K ~20 pages Confidential Yaky Yanay Chief Financial Officer Pluristem Therapeutics Inc. Matam Advanced Technology Park # 20 Haifa 31905, Israel Dear Mr. Yanay

from 10QSB ~5 pages Pluristem Life Systems Inc. Code of Business Conduct and Ethics and Compliance Program Adopted October 2, 2003